Supplemental Approvals

Generic Name (Trade Nameâ€”Company)	**Uses**/Notes
August 30, 2018	
Lenvatinib ***(Lenvima—Eisai Inc.)*** **Lenvatinib has new indication for treatment of unresectable hepatocellular carcinoma**	FDA has approved lenvatinib capsules for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on an international, multicenter, randomized, open-label, noninferiority trial conducted in 954 patients with previously untreated, metastatic or unresectable HCC. Patients were randomized (1:1) to receive lenvatinib (12 mg orally once daily for patients with a baseline body weight of ?60 kg and 8 mg orally once daily for patients with a baseline body weight of

Source URL:

http://www.aphanet.org/supplemental-approvals/lenvatinib-has-new-indication-treatment-unresectable-hepatocellular-carcinoma